Why should you attend?

Although the US remains the leader in biotech, Asian countries, riding on their success in high tech development, have rapidly focused their resources in biotechnology. The objective of the Forum is to set up an efficient platform for global biotech sectors to execute and maintain business deal flows and to foster collaborations between the US and Taiwan biotech companies.

What value does this Bioforum bring?

We bring in distinguished speakers to share their success in cross-Pacific business deals and allow face-to-face discussion between participants.
Here are some highlights of our speakers and their success:

• Dr. Rong-Hwa Lin, CEO, AbGenomics, Taiwan. Recently signed an exclusive licensing agreement with Boehringer Ingelheim to develop, manufacture and commercialize products derived from AbGenomics Corporation’s antibody 168.
• Dr. Charles C.-Y. Shih, CEO, Androscience, San Diego. Dr. Shih successfully started his company by raising multi-million dollar capital in Taiwan and set up operation in San Diego, California.
• Dr. Kam Li, Partner, Procopio, Cory, Hargreaves & Savitch LLP, San Diego - Dr. Li is experienced in many aspects of global partnering relationships, including strategic partnering negotiations, technology acquisition, licensing, joint research, development and production projects and distribution relationships. He has represented companies in the U.S., China, and other countries.

To see the complete list of speakers, please click "Speaker Profile"

Why Taiwan?

Taiwan, much smaller than the state of California in size, is the home of the No. 1 global maker of notebook PCs and the biggest chip foundry on the planet. Experts predicted that the total revenue of Taiwan’s 25 key tech companies should reach $122 billion this year. The Full story appeared on May 16th issue of BusinessWeek: Why Taiwan Matters.

Now Taiwan is diversifying itself from high-tech to biotech. The Taiwan National Science Council has set up 4 Science Parks to help drive biotech research and development. In addition, many government incentives are available to the tenants of these science parks. Venture capital firms and large companies’ VC funds began to have life-science oriented portfolios. Medical device and biopharmaceutical companies also collaborate with foreign companies for R&D, licensing, and distribution deals.